Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
- PMID: 23808545
- DOI: 10.1021/jm400487c
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
Abstract
Restoration of p53 activity by inhibition of the p53-MDM2 interaction has been considered an attractive approach for cancer treatment. However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of small-molecule inhibitors with desirable pharmacological profiles. RG7112 was the first small-molecule p53-MDM2 inhibitor in clinical development. Here, we report the discovery and characterization of a second generation clinical MDM2 inhibitor, RG7388, with superior potency and selectivity.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials
Miscellaneous